EpiScore allowed splitting patients with DLBCL in three risk groups: group 1 (low risk, low expression of DNMT3A, DOT1L and SETD8), group 2 (medium risk, high expression of one of these three genes), and group 3 (high risk, high expression of two or all three genes). This evidence concerns the gene DNMT3A and diffuse large B-cell lymphoma.